News Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse Staff September 11, 2023 Post Navigation Previous APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)Next Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer More Stories Healthcare News HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference Staff December 23, 2024 Clinical Trial News Pharmaceutical Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ Staff December 23, 2024 Cancer News Pharmaceutical The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids Staff December 23, 2024
